KRAS G12C

Clinical trials for KRAS G12C explained in plain language.

Never miss a new study

Get alerted when new KRAS G12C trials appear

Sign up with your email to follow new studies for KRAS G12C, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New pill takes on hard-to-treat KRAS cancers in first human trial

Disease control Recruiting now

This early-phase study tests a new drug called BBO-11818 in adults with advanced lung, pancreatic, or colorectal cancers that have a KRAS mutation. The main goals are to check safety and find the best dose, while also seeing if the drug can shrink tumors. About 387 participants w…

Matched conditions: KRAS G12C

Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control

Last updated May 01, 2026 15:59 UTC

KRAS G12C

Get alerted when new KRAS G12C trials appear

New pill takes on hard-to-treat KRAS cancers in first human trial